La chaîne d'options affiche les données clés des options sur actions de Innovation Beverage Group à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Innovation Beverage Group..

Innovation Beverage Group (NASDAQ:IBG) Stock, Chaîne d'Options

Innovation Beverage Group

Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter and retailer of a growing beverage portfolio of 60 formulations across 13 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands.

Innovation Beverage Group Limited - Ordinary Shares

Innovation Beverage Group Ltd

iShares iBonds Dec 2044 Term Treasury ETF

iShares iBonds Dec 2045 Term Treasury ETF

iShares iBonds Dec 2054 Term Treasury ETF

iShares iBonds Dec 2055 Term Treasury ETF

NEXUS ENERGY SERVICES INC by Nexus Energy Services, Inc.

Nexus Energy Services Inc

Rosenblatt analyst Mike Genovese upgrades Coherent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>) from Neutral to Buy and lowers the price target from $115 to $85.

News

Upgrades

Price Target

Analyst Ratings

COHR

Rosenblatt Upgrades Coherent to Buy, Lowers Price Target to $85

AerCap Closes Q1 2025 With 112 Lease Deals, $1.5B Financing, And $558M Share Buyback

HC Wainwright &amp; Co. analyst Yi Chen reiterates Kala Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALA#NASDAQ">KALA</a>) with a Buy and maintains $15 price target.

Reiteration

KALA

HC Wainwright & Co. Reiterates Buy on Kala Bio, Maintains $15 Price Target

Macro Economic Events

Economics

China Earlier Announced 34% Tariff On All U.S. Imports Starting April 10 In Response To U.S.Tariffs Imposed By President Trump

Telsey Advisory Group analyst Dana Telsey maintains Guess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) with a Market Perform and maintains $13 price target.

Telsey Advisory Group Maintains Market Perform on Guess, Maintains $13 Price Target

MSSA

Metal Sky Star To Be Delisted From Nasdaq After SPAC Deadline Miss, Will Move To OTC Market

HC Wainwright &amp; Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VANI#NASDAQ">VANI</a>) with a Buy and maintains $4 price target.

VANI

HC Wainwright & Co. Reiterates Buy on Vivani Medical, Maintains $4 Price Target

Telsey Advisory Group analyst Joseph Feldman maintains Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) with a Outperform and maintains $1100 price target.

COST

Telsey Advisory Group Maintains Outperform on Costco Wholesale, Maintains $1100 Price Target

UTHR

United Therapeutics Corporation Says It Will Feature Clinical Data Across Its Commercial And Development Portfolio At International Society For Heart And Lung Transplantation 45th Annual Meeting And Scientific Sessions

<ul>
<li>Late-breaking oral presentation of results from the positive pivotal ACCORD-2 Phase 3 trial of AXS-05 in Alzheimer's disease agitation&nbsp;</li>
<li>Presentation featuring network meta-analysis of SYMBRAVO versus oral CGRPs</li>
</ul>

Biotech

Health Care

General

AXSM

Axsome Therapeutics Announced Multiple Presentations At The 2025 American Academy Of Neurology Annual Meeting

NYAX

Nayax Plans To Maintain Current Hardware Pricing For US Customers, Despite New Tariffs Imposed On Imports To US

Telsey Advisory Group analyst Dana Telsey maintains G-III Apparel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>) with a Market Perform and maintains $30 price target.

GIII

Telsey Advisory Group Maintains Market Perform on G-III Apparel Group, Maintains $30 Price Target

<ul>
<li>Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year.</li>
<li>Approval brings AstraZeneca and Daiichi Sankyo's Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease.</li>
</ul>

Large Cap

The European Commission Approves AstraZeneca And Daiichi Sankyo's Enhertu (Trastuzumab Deruxtecan) As Monotherapy For Adult Patients With Unresectable Or Metastatic Hormone Receptor-positive, HER2-low Or HER2-ultralow Breast Cancer Who Have Received At Least One Endocrine Therapy In The Metastatic Setting And Who Are Not Considered Suitable For Endocrine Therapy As The Next Line Of Treatment

ARVN

Arvinas Says It Presented First-in-Human Data For Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, And Central And Peripheral LRRK2 Degradation

In this regimen, patients are treated with Imfinzi in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery.
&nbsp;

The European Commission Approves AstraZeneca's Imfinzi (Durvalumab) In Combination With Chemotherapy For Adults With Resectable Non-small Cell Lung Cancer At High Risk Of Recurrence And No Epidermal Growth Factor Receptor Mutations Or Anaplastic Lymphoma Kinase Rearrangements

HC Wainwright &amp; Co. analyst Ed Arce reiterates Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) with a Buy and maintains $7.5 price target.

AKBA

HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $7.5 Price Target

Telsey Advisory Group analyst Cristina Fernandez maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Outperform and maintains $220 price target.

Telsey Advisory Group Maintains Outperform on Williams-Sonoma, Maintains $220 Price Target

The most oversold stocks in the consumer discretionary sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">JAKKS Pacific Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAKK#NASDAQ">JAKK</a>)</h3>
<ul>
<li>On March 18, Small Cap Consumer Research analyst Eric Beder reiterated Jakks Pacific with a Buy and maintained a $40 price target. The company's stock fell around 15% over the past five days and has a 52-week low of $17.06.</li>
<li>RSI Value: 25.2</li>
<li>JAKK Price Action: Shares of JAKKS Pacific fell 13.9% to close at $21.36 on Thursday.</li>
<li>Edge Stock Ratings: 39.60 Momentum score with Value at 94.24. </li>
</ul>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/JAKK"><img loading="lazy" decoding="async" width="437" height="177" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035725/image-40.png" alt="" class="wp-image-857015" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035725/image-40.png 437w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035725/image-40-300x122.png 300w" sizes="(max-width: 437px) 100vw, 437px" /></a></figure>
<h3 class="wp-block-heading">Haverty Furniture Companies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HVT#NYSE">HVT</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Feb. 24, Haverty Furniture reported fourth-quarter financial results and beat its EPS and revenue estimates. Steven G. Burdette, President and CEO, said, &#8220;Our team remained disciplined in managing our operations and executing our growth strategies, even amidst the housing slowdown. We achieved our goal of opening five net new stores in 2024, with a notable return to the Houston, TX market after approximately 40 years, where we now have two stores.&#8221; The company's stock fell around 17% over the past month and<a href="https://www.benzinga.com/quote/HVT"> has a 52-week low </a> of $17.78.</li>
<li>RSI Value: 27.1</li>
<li>HVT Price Action: Shares of Haverty Furniture dipped 13% to close at $17.88 on Thursday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0404">HVT stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0404"><img loading="lazy" decoding="async" width="925" height="828" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035823/image-1-12.png" alt="" class="wp-image-857016" style="width:554px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035823/image-1-12.png 925w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035823/image-1-12-300x269.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035823/image-1-12-768x687.png 768w" sizes="(max-width: 925px) 100vw, 925px" /></a></figure>
<h3 class="wp-block-heading">Six Flags Entertainment Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUN#NYSE">FUN</a>)</h3>
<ul>
<li>On March 25, Truist Securities analyst Michael Swartz maintained Six Flags Entertainment with a Buy and lowered the price target from $56 to $52. The company's stock fell around 21% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/FUN">low of $31.33.</a></li>
<li>RSI Value: 27.7</li>
<li>FUN Price Action: Shares of Six Flags Entertainment fell 14.4% to close at $31.98 on Thursday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0404">FUN shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0404"><img loading="lazy" decoding="async" width="900" height="833" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035927/image-41.png" alt="" class="wp-image-857017" style="width:518px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035927/image-41.png 900w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035927/image-41-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035927/image-41-768x711.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a> 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44626468/top-3-risk-off-stocks-that-are-ticking-portfolio-bombs">Top 3 Risk Off Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

JAKK

Top 3 Consumer Stocks That Are Set To Fly This Quarter

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates BiomX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PHGE#AMEX">PHGE</a>) with a Buy and maintains $21 price target.

PHGE

HC Wainwright & Co. Reiterates Buy on BiomX, Maintains $21 Price Target

Needham analyst Scott Berg reiterates Thryv Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRY#NASDAQ">THRY</a>) with a Buy and maintains $28 price target.

THRY

Needham Reiterates Buy on Thryv Holdings, Maintains $28 Price Target

After Marking Multiple Milestones On Growth Journey Including Nasdaq Listing, Innovation Beverage Group Eyes Further Global Expansion Through Deep Beverage Portfolio

Press Releases

Innovation Beverage Group Receives Largest Shipment of Its Top-Selling Bitters to Date in the U.S. - Ready to Meet Growing Demand from Expanding Distribution Network

Innovation Beverage Group Offers Zero-Alcohol Range As Non-Alcoholic Beverages Market Grows

Investing In Craft: The Benefits Of Boutique Brands Like IBG's Australian Bitters

Innovation Beverage Group to Boost Sales of Its Bitters Brands in the U.S. Through Strategic Alliance With Blue Ridge Spirits & Wine Marketing

Management

Innovation Beverage Group Appoints Sahil Beri as Interim CEO and Announces Further Expansion Into Eastern U.S.

Managing Director Appointment and CEO Resignation

Innovation Beverage Group's Bitters Captures 45% Market Share in Australia Driven by 2024 Sales Growth

Innovation Beverage Group Expands U.S. Distribution of its Award-Winning Bitters Through One of the Nation's Largest Beverage Alcohol Distributors

AUNXF

DASH

TSXV:MMC

TSXV:TLC

UBER

Amaze Holdings

Brown Forman Inc Class A Common Stock

Brown Forman Inc Class B Common Stock

Beeline Holdings

Heritage Distilling Holding Company, Inc. - Common Stock

Heritage Distilling Hldg

Diageo

MGP Ingredients

Splash Beverage Group, Inc. (NV) Common Stock

Splash Beverage Group

Constellation Brands

Willamette Valley Vineyards, Inc. - Common Stock

Comments

Innovation Beverage Group

Innovation Beverage Group (IBG) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL